Allosteric regulation of γ-secretase activity by a phenylimidazole-type γ-secretase modulator

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 29, 2014, Pages 10544-10549

  Takeo, Koji ^a   Tanimura, Shun ^a,c   Shinoda, Takehiro ^c   Osawa, Satoko ^a   Zahariev, Ivan Krasmirov ^a   Takegami, Naoki ^a,b,d   Ishizuka Katsura, Yoshiko ^c   Shinya, Naoko ^c   Takagi Niidome, Shizuka ^a   Tominaga, Aya ^a   Ohsawa, Noboru ^c   Kimura Someya, Tomomi ^c   Shirouzu, Mikako ^c   Yokoshima, Satoshi ^a   Yokoyama, Shigeyuki ^c   Fukuyama, Tohru ^a   Tomita, Taisuke ^a,e   Iwatsubo, Takeshi ^a,d,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c RIKEN   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Allosteric modulator; Alzheimer's disease; Amyloid protein; Chemical biology; Intramembrane proteolysis

Indexed keywords

AMYLOID BETA PROTEIN; GAMMA SECRETASE; GAMMA SECRETASE MODULATOR; NOOTROPIC AGENT; PRESENILIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; ENZYME ACTIVE SITE; MOUSE; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ALLOSTERIC MODULATOR; ALZHEIMER'S DISEASE; AMYLOID-Β PROTEIN; CHEMICAL BIOLOGY; INTRAMEMBRANE PROTEOLYSIS;

ALLOSTERIC REGULATION; AMINO ACIDS; AMYLOID PRECURSOR PROTEIN SECRETASES; CATALYTIC DOMAIN; ENZYME ACTIVATION; FLUORESCENCE; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; MUTATION; PEPTIDES; STRUCTURAL HOMOLOGY, PROTEIN; SUBSTRATE SPECIFICITY;

EID: 84904613573     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1402171111     Document Type: Article

References (47)

1. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's disease: The challenge of the second century. Sci Transl Med 3(77):sr1.
2. Tomita T, Iwatsubo T (2013) Structural biology of presenilins and signal peptide peptidases. J Biol Chem 288(21):14673-14680.
3. Takasugi N, et al. (2003) The role of presenilin cofactors in the γ-secretase complex. Nature 422(6930):438-441. (Pubitemid 36411397)
4. Qi-Takahara Y, et al. (2005) Longer forms of amyloid β protein: Implications for the mechanism of intramembrane cleavage by γ-secretase. J Neurosci 25(2):436-445. (Pubitemid 40105614)
5. Takami M, et al. (2009) γ-Secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of β-carboxyl terminal fragment. J Neurosci 29(41):13042-13052.
6. Iwatsubo T, et al. (1994) Visualization of A β 42(43) and A β 40 in senile plaques with end-specific A β monoclonals: Evidence that an initially deposited species is A β 42(43). Neuron 13(1):45-53.
7. Doody RS, et al.; Alzheimer's Disease Cooperative Study Steering Committee; Semagacestat Study Group (2013) A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 369(4):341-350.
8. Weggen S, et al. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414(6860):212-216. (Pubitemid 33051236)
9. Kounnas MZ, et al. (2010) Modulation of γ-secretase reduces β-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67(5):769-780.
10. Oehlrich D, Berthelot DJ, Gijsen HJ (2011) γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem 54(3):669-698.
11. Ebke A, et al. (2011) Novel γ-secretase enzyme modulators directly target presenilin protein. J Biol Chem 286(43):37181-37186.
12. Pozdnyakov N, et al. (2013) γ-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem 288(14):9710-9720.
13. Li X, et al. (2013) Structure of a presenilin family intramembrane aspartate protease. Nature 493(7430):56-61.
14. Fischer C, et al. (2008) Triazole derivatives for treating alzheimer's disease and related conditions. International patent WO2008156580.
15. Micchelli CA, et al. (2003) γ-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J 17(1):79-81.
16. Imamura Y, et al. (2009) Inhibition of γ-secretase activity by helical β-peptide foldamers. J Am Chem Soc 131(21):7353-7359.
17. Kornilova AY, Bihel F, Das C, Wolfe MS (2005) The initial substrate-binding site of γ-secretase is located on presenilin near the active site. Proc Natl Acad Sci USA 102(9):3230-3235. (Pubitemid 40328028)
18. Takahashi Y, et al. (2003) Sulindac sulfide is a noncompetitive γ-secretase inhibitor that preferentially reduces Aβ 42 generation. J Biol Chem 278(20):18664-18670. (Pubitemid 36799494)
19. Hayashi I, et al. (2004) Selective reconstitution and recovery of functional γ-secretase complex on budded baculovirus particles. J Biol Chem 279(36):38040-38046. (Pubitemid 39195520)
20. Ogura T, et al. (2006) Three-dimensional structure of the γ-secretase complex. Biochem Biophys Res Commun 343(2):525-534, and correction (2006) 345(1):543.
21. Farmery MR, et al. (2003) Partial purification and characterization of γ-secretase from post-mortem human brain. J Biol Chem 278(27):24277-24284. (Pubitemid 37548577)
22. Shimono K, et al. (2009) Production of functional bacteriorhodopsin by an Escherichia coli cell-free protein synthesis system supplemented with steroid detergent and lipid. Protein Sci 18(10):2160-2171.
23. Ahn K, et al. (2010) Activation and intrinsic γ-secretase activity of presenilin 1. Proc Natl Acad Sci USA 107(50):21435-21440.
24. Ohki Y, et al. (2011) Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J 30(23):4815-4824.
25. Herreman A, et al. (2000) Total inactivation of γ-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2(7):461-462.
26. Ma G, Li T, Price DL, Wong PC (2005) APH-1a is the principal mammalian APH-1 isoform present in γ-secretase complexes during embryonic development. J Neurosci 25(1):192-198. (Pubitemid 40110780)
27. Page RM, et al. (2008) Generation of Aβ38 and Aβ42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and γ-secretase modulation. J Biol Chem 283(2):677-683.
28. de Graaf C, Rein C, Piwnica D, Giordanetto F, Rognan D (2011) Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors. ChemMedChem 6(12):2159-2169.
29. Takagi S, Tominaga A, Sato C, Tomita T, Iwatsubo T (2010) Participation of transmembrane domain 1 of presenilin 1 in the catalytic pore structure of the γ-secretase. J Neurosci 30(47):15943-15950.
30. Sato C, Morohashi Y, Tomita T, Iwatsubo T (2006) Structure of the catalytic pore of γ-secretase probed by the accessibility of substituted cysteines. J Neurosci 26(46):12081-12088. (Pubitemid 44772118)
31. Tomita T, et al. (2001) The first proline of PALP motif at the C terminus of presenilins is obligatory for stabilization, complex formation, and γ-secretase activities of presenilins. J Biol Chem 276(35):33273-33281.
32. Sato C, Takagi S, Tomita T, Iwatsubo T (2008) The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the γ-secretase. J Neurosci 28(24):6264-6271.
33. Takeo K, Watanabe N, Tomita T, Iwatsubo T (2012) Contribution of the γ-secretase subunits to the formation of catalytic pore of presenilin 1 protein. J Biol Chem 287(31):25834-25843.
34. Crump CJ, et al. (2011) Piperidine acetic acid based γ-secretase modulators directly bind to Presenilin-1. ACS Chem Neurosci 2(12):705-710.
35. Okochi M, et al. (2013) γ-secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43. Cell Reports 3(1):42-51.
36. Chávez-Gutiérrez L, et al. (2012) The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J 31(10):2261-2274.
37. Acx H, et al. (2014) Signature amyloid β profiles are produced by different γ-secretase complexes. J Biol Chem 289(7):4346-4355.
38. Serneels L, et al. (2009) γ-Secretase heterogeneity in the Aph1 subunit: Relevance for Alzheimer's disease. Science 324(5927):639-642.
39. Watanabe N, et al. (2010) Functional analysis of the transmembrane domains of presenilin 1: Participation of transmembrane domains 2 and 6 in the formation of initial substrate-binding site of γ-secretase. J Biol Chem 285(26):19738-19746.
40. Uemura K, et al. (2010) Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric site. Nat Commun 1:130.
41. Ohki Y, et al. (2014) Binding of longer Aβ to transmembrane domain 1 of presenilin 1 impacts on Aβ42 generation. Mol Neurodegener 9:7.
42. Focke PJ, Wang X, Larsson HP (2013) Neurotransmitter transporters: Structure meets function. Structure 21(5):694-705.
43. Gong P, et al. (2010) Mutation analysis of the presenilin 1 N-terminal domain reveals a broad spectrum of γ-secretase activity toward amyloid precursor protein and other substrates. J Biol Chem 285(49):38042-38052.
44. Bondar AN, del Val C, White SH (2009) Rhomboid protease dynamics and lipid interactions. Structure 17(3):395-405.
45. Lupardus PJ, Shen A, Bogyo M, Garcia KC (2008) Small molecule-induced allosteric activation of the Vibrio cholerae RTX cysteine protease domain. Science 322(5899):265-268.
46. Morohashi Y, et al. (2006) C-terminal fragment of presenilin is the molecular target of a dipeptidic γ-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). J Biol Chem 281(21):14670-14676. (Pubitemid 43855171)
47. Tomita T, et al. (1997) The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 94(5):2025-2030. (Pubitemid 27113955)